Co-Diagnostics (NASDAQ:CODX) +176% on eliminating debt.Eyenovia (NASDAQ:EYEN) +52% on positive MicroStat data.Ekso Bionics Holdings (NASDAQ:EKSO) +33% on $100M JV to develop the...
Novavax (NASDAQ:NVAX) initiated with Outperform rating and $4 (87% upside) price target at Oppenheimer. Shares up 3% premarket.Synthetic Biologics (NYSEMKT:SYN) initiated with...
BioTime (BTX) Q3 results: Revenues: $1M (-41.2%).Net Income: $66.7M; EPS: $0.53; CF Flow Ops: ($25.1M) (-1.2%).Shares are down 2% premarket.Previously: BioTime EPS of $0.53...
Lineage Cell Therapeutics, Inc. (NYSE:LCTX) has been struggling lately, but the selling pressure may be coming to an end soon. That is because LCTX recently saw a Hammer Chart...
Aytu BioScience, Inc. (NASDAQ:AYTU) was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more...
BioTime, Inc. (NYSE:BTX) was a big mover last session, as the company saw its shares rise 6% on the day. The move came on solid volume too with far more shares changing hands...
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cell therapies to address unmet medical needs. The Company designs, develops, and manufactures specialized human cells with anatomical and physiological functions which are similar or identical to cells found naturally in the human body. It has three allogeneic product candidates: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium (RPE) cell replacement therapy, which is in a Phase I/IIa multicenter clinical trial for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy (GA). OPC1 is an oligodendrocyte progenitor cell therapy, which is in a follow-up for a Phase I/IIa multicenter clinical trial for spinal cord injuries (SCI). VAC is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells. Its VAC product candidates include, VAC2, which is in a Phase I clinical trial in non-small cell lung cancer (NSCLC).
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Buy | Neutral | Sell |
| Technical Indicators | Sell | Strong Buy | Strong Buy | Sell | Strong Sell |
| Summary | Neutral | Strong Buy | Strong Buy | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 194.28 | 195.42 | 191.93 | +3.56 | +1.87% | 836.29K | NYSE | |||
| 244.24 | 251.62 | 243.05 | +0.13 | +0.05% | 4.15M | NASDAQ | |||
| 48.74 | 49.13 | 48.30 | -1.21 | -2.41% | 15.02M | NYSE | |||
| 8.30 | 8.57 | 8.26 | -0.15 | -1.77% | 2.10M | NYSE | |||
| 297.00 | 305.61 | 294.50 | -6.25 | -2.06% | 1.48M | NASDAQ | |||
| 31.41 | 31.67 | 31.32 | +0.56 | +1.80% | 2.16M | NYSE | |||
| 352.57 | 356.02 | 349.77 | +4.66 | +1.34% | 873.72K | NYSE | |||
| 1.215 | 1.24 | 1.20 | +0.0250 | +2.10% | 1.84M | NYSE | |||
| 100.26 | 102.37 | 99.13 | +1.21 | +1.22% | 35.08M | NASDAQ | |||
| 45.10 | 46.12 | 45.09 | -0.81 | -1.76% | 629.60K | NYSE | |||
| 1.07 | 1.14 | 1.05 | 0.0000 | 0.00% | 191.95K | NYSE | |||
| 95.14 | 97.71 | 93.63 | +2.71 | +2.93% | 10.14M | NYSE | |||
| 3.55 | 3.63 | 3.515 | +0.040 | +1.14% | 5.97M | NYSE | |||
| 44.13 | 44.37 | 44.11 | +0.25 | +0.56% | 3.68M | NYSE | |||
| 36.74 | 37.49 | 36.71 | -0.59 | -1.58% | 346.82K | NYSE |